

Amendments to the Claims:

Please cancel Claims 3, 131-133 and 146-149 without prejudice or disclaimer, amend Claim 1, and add new Claim 150 as set forth below.

1. (Currently amended) A compound comprising a ligand that specifically reacts with a first receptor not naturally present in mammals, and wherein the compound further comprises a molecular cage covalently bound to the ligand that prevents reaction of the ligand with the first receptor, wherein the ligand is released from the cage and capable of reacting with the first receptor upon exposure of the compound to light and wherein the ligand is a steroid.

2. (Original) The compound of claim 1, wherein the first receptor is an ecdysone receptor.

3. (Canceled)


4. (Original) The compound of claim 1, wherein the ligand is an inhibitor of the first receptor.

5. (Original) The compound of claim 2, wherein the ligand is selected from the group consisting of ecdysone, 20-hydroxyecdysone, ponasterone A, muristerone A, inokosterone, 3,5-di-*tert*-butyl-4-hydroxy-N-isobutyl-benzamide and a dibenzoylhydrazine.

6. (Original) The compound of claim 1, wherein the molecular cage is a nitromethoxybenzyl moiety.

7. (Original) The compound of claim 6, wherein the nitromethoxybenzyl moiety is 1-methyl-4,5-dimethoxy-2-nitrobenzene.

8. (Previously presented) The compound of claim 7, wherein the compound is



9-10. (Canceled)

11. (Original) The compound of claim 1, wherein the molecular cage is a two-photon cage.

12-143. (Canceled)

144. (Previously presented) The compound of claim 1, wherein the light comprises wavelengths at 300-400 nm.

145. (Previously presented) The compound of claim 1, wherein the light comprises wavelengths at 325-375 nm.

146-149. (Canceled)

Application No.: 10/532,009

Applicants: David Lawrence et al.

Filed: November 16, 2005

150. (New) The compound of claim 7, wherein the compound is

